J&J's Christine Poon accepts additional roles

Christine Poon, worldwide chairman, medicines and nutritionals, and member of the executive committee of Johnson & Johnson was appointed as vice chairman of the company.
With this appointment, Poon becomes a member of the office of the chairman, joining chairman and chief executive, William Weldon and vice chairman and chief financial officer, Robert Darretta.
In addition, the nominating & corporate governance committee of the board of directors has nominated Poon for election to the board at the annual meeting of shareholders in April.
Poon will continue to have management responsibility for all pharmaceutical, consumer pharmaceutical, and nutritional businesses and report directly to Weldon.
"Since her arrival, our pharmaceutical business has become one of the fastest growing in the industry," Weldon said. "Simultaneously, Chris has championed our pharmaceutical R&D organization as it develops and supports a robust pipeline of new medicines. She has exhibited strong leadership and personal involvement in building a skilled and diverse workforce. I look forward to her deeper contributions in strategic planning and talent development."
Poon's achievements in pharmaceuticals earned her the honor of being named the 2004 Healthcare Businesswomen's Association (HBA) Woman of the Year.
She is a member of the advisory board of the HBA and is on the board of directors of the Fox Chase Cancer Center in Philadelphia, Pa.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.